tirzepatide news 2025 New clinical trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss Tirzepatide is NO longer in

This rebound occurs because semaglutide masks underlying hunger signals and metabolic patterns rather than permanently rewiring them, meaning your body's natural appetite-regulation pathways remain unchanged once the drug leaves your system

Typically, when youve eaten enough, you should get a signal to the brain that youre full

Chianelli, M

Reduced potency from expired medication may mean your glucose levels are higher than expected

(2015) "MOTS-c promotes metabolic homeostasis." Published in Cell Metabolism

If left untreated, hyperthyroidism can lead to major issues such as heart disease, bone loss, and, in severe circumstances, a life-threatening thyroid storm